News | December 31, 2015

VolparaDensity Goes Mobile with Installation at Saint Joseph Hospital in Denver

First breast center installation including a mobile mammography system 

VolparaDensity Goes Mobile with Installation at Saint Joseph Hospital in Denver

December 31, 2015 — Volpara Solutions has gone mobile with the first-ever installation of VolparaDensity in a mobile mammography unit at Saint Joseph Hospital in Denver. The VolparaDensity installation in Saint Joseph’s mobile mammography unit and their award-winning Breast Care Center, highlights the tremendous growth Volpara Solutions has experienced in 2015. VolparaDensity has been installed on more than 150 digital mammography systems in 2015, surpassing more than 500 systems at customer sites globally.

With installations recently completed at such sites as Shiela R. Veloz Breast Center, Oaklawn Hospital, Penn State Hershey Medical Center, Munson Medical Center, and many more, Volpara Solutions technology is now in use in 33 countries and more than 7 million women have had their breast density analysed using VolparaDensity.

Located in the heart of downtown Denver, the Saint Joseph Hospital Breast Care Center carries American College of Radiology (ACR) Breast Imaging Center of Excellence designation and is also part of the National Accreditation Program for Breast Centers and a U.S. Department of Health and Human Services Certified Mammography Facility. The Volpara Solutions installation at Saint Joseph Hospital provides the ability to offer objective breast density values and volumetric performance metrics for all 8,000+ mammograms performed annually on two Hologic mammography systems in the Breast Center, as well in the advanced mobile mammography system.

“At Saint Joseph Hospital we pride ourselves on a tradition of providing excellent breast health care to every patient. We’ve made a commitment to include objective, volumetric breast density assessment as our standard of care and make it available to every woman who receives her mammogram from Saint Joseph Hospital, whether it’s in the Breast Center or during one of the preventive screening events performed by our mobile mammography unit,” said Pam Heller, RT, Clinical Manager at Saint Joseph Hospital’s Breast Care Center. “The addition of VolparaDensity enables us to thoroughly and accurately measure breast density for every woman we serve, improving our ability to detect breast cancer as early as possible.”

Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis data and to determine which women would benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the fourth and fifth Editions of the Breast Imaging-Reporting and Data System (BI-RADS) Atlas from the American College of Radiology (ACR). VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening.

“With extensive validation of the ability of volumetric breast density assessment to help overcome the limitations of mammography, combined with pivotal research demonstrating a strong link between breast cancer risk and density, we have seen significant adoption of VolparaDensity and our suite of quantitative breast imaging solutions,” said Ralph Highnam, Ph.D., CEO and chief scientist, Volpara Solutions. “With tremendous direct customer relationships and partnerships with key OEM partners like Siemens, GE Healthcare and Gamma Medica, not only have we experienced strong growth this year, but we have also generated a strong order pipeline going coming out of RSNA and into next year.”

For more information: www.SaintJosephDenver.org, www.volparasolutions.com

Related Content

Researchers developed a deep learning model that identifies imaging biomarkers to predict a patient’s risk for developing breast cancer

A deep learning model was developed that combined imaging and traditional risk factors.

News | Mammography | November 30, 2020
November 30, 2020 — Researchers at Massachusetts General Hospi...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.